Compare CNTB & MGYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNTB | MGYR |
|---|---|---|
| Founded | 2012 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 116.3M |
| IPO Year | 2020 | 2021 |
| Metric | CNTB | MGYR |
|---|---|---|
| Price | $2.44 | $17.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 437.6K | 3.8K |
| Earning Date | 08-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.30% |
| EPS Growth | N/A | ★ 26.83 |
| EPS | N/A | ★ 0.98 |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.81 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $16.03 |
| 52 Week High | $3.82 | $20.00 |
| Indicator | CNTB | MGYR |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | 44.07 |
| Support Level | $2.30 | $16.87 |
| Resistance Level | $2.68 | $17.24 |
| Average True Range (ATR) | 0.17 | 0.21 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 94.83 | 9.99 |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
Magyar Bancorp Inc is an independent, community financial services provider offering traditional banking services to individual, business, and government customers. The Company attracts retail deposits through its main office in New Brunswick, New Jersey, and branch offices in Middlesex and Somerset Counties, and invests those funds mainly in commercial and residential real estate loans, commercial business loans, SBA loans, home equity loans and lines of credit, construction and land loans, and investment securities. Revenues are derived mainly from interest on loans and securities and from fees and service charges, with lending relationships focused on small to mid-sized businesses and individual consumers in central and northern New Jersey.